Thomas A. Haag is a partner in the Intellectual Property Department of Seyfarth Shaw LLP’s Washington D.C. office where he co-chairs the firm’s Chemical & Life Sciences Patent Team. His practice focuses on pharmaceutical and biotechnology patent litigation, due diligence, prosecution and licensing/transactional matters; and in particular Hatch-Waxman litigation and Biosimilars related matters.
He has extensive experience creating and strategically managing large patent portfolios, as well as drafting and negotiating biomedical patent licenses, asset purchase agreements and joint-development agreements. Dr. Haag’s technical expertise is in molecular biology related technologies including those in the fields of immuno-oncology, cancer/infectious disease vaccines, nucleic acid-based therapeutics, stem-cell therapeutics, gene editing and therapy, epigenetics, transgenic plants, next generation sequencing (NGS), biologics and biosimilars.
Previously, Dr. Haag was a Founding Partner and Chair of Fanelli Haag PLLC. Fanelli Haag was acquired by Seyfarth Shaw LLP in October 2016. Fanelli Haag was a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, nanotechnology and chemical industries.
Dr. Haag has firsthand experience in translating biotechnologies into successful commercial ventures. While at Fanelli Haag, Dr. Haag served as acting CEO of PhosImmune, Inc., an immuno-oncology neoantigen discovery startup company co-founded and built by Fanelli Haag and ultimately acquired by Agenus, Inc. (NASDAQ: AGEN) in December 2015. Prior to founding Fanelli Haag, Dr. Haag served as General Counsel of Arrowhead Research Corporation (NASDAQ: ARWR), a private equity firm focused on investments in the life sciences industry.
Prior to Arrowhead, Dr. Haag was in private practice in the Washington D.C. offices of two international law firms, where he was involved in Hatch-Waxman litigation, prosecuted biotechnology patents, drafted formal opinions of counsel and gained experience in coordinating IP and FDA regulatory strategies.
Dr. Haag graduated from The George Washington University Law School with honors, where he also received the ABA/BNA Award for Excellence in the Study of Intellectual Property Law. During law school he was an intern at the German Federal Patent Court, and a 2002 Fellow of the Research Fund of the European Patent Organization for a project completed at the Max Planck Institute for Intellectual Property, Competition and Tax Law in Munich. Dr. Haag received a B.S. in Biology and Ph.D. in Molecular, Cell & Developmental Biology from UCLA where he was an NIH Pre-Doctoral Fellow in Genetic Mechanisms.
Dr. Haag was selected to be a 2005 Manfred Wörner Fellow of the German Marshall Fund of the United States. Additionally he has served as Delegate-at-Large to the Legal Affairs Committee of NATO’s Interallied Confederation of Reserve Officers (CIOR). He speaks both English and German at a native level.
- J.D., The George Washington University Law School, with honors
- Ph.D. in Molecular, Cell & Developmental Biology, University of California, Los Angeles
- B.S. in Biology, University of California, Los Angeles
Rate : $$$